High Throughput Screening Market (Cell Based, Ultra High Throughput Screening, Bioinformatics) Worth $19,626.54 Million by 2018 – New Report by MarketsandMarkets
High Throughput Screening (HTS) is a drug-discovery process that leverages automation to quickly assay the biochemical activity of numerous drug-like compound – http://www.marketsandmarkets.com/Market-Reports/high-throughput-screening-market-134981950.html.
(PRWEB) February 24, 2014
According to the new market research report the “High Throughput Screening (HTS) Market by Technology (Cell Based, Ultra High Throughput Screening (UHTS), Label Free, Bioinformatics), by Applications (Target Identification, Primary Screening, Toxicology, Stem Cell) & by End Users (Pharmaceutical Industry, Biotechnology Industry, CRO) – Forecast to 2018” analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World.
Browse 75 tables and 23 figures spread through 245 pages and in-depth TOC on "High Throughput Screening (HTS) Market"
Early buyers will receive 10% customization on this report.
Inquiry Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=134981950
This report studies the global high throughput screening (HTS) market over the forecast period of 2013 to 2018. The global HTS market was valued at an estimated $13,735.88 million in 2013 and is poised to grow at a CAGR of 7.4% from 2013 to 2018, to reach $19,626.54 million by 2018.
A number of factors such as technological innovations, open innovation models adopted by pharmaceutical companies, increasing drug discovery initiatives by academic institutions, and huge capital investments in the HTS technology by organizations are driving the growth of the HTS market. Moreover, the presence of a large untapped market in emerging countries and the incessant rise in outsourced drug discovery services especially in China and India are the various growth opportunities in this market. However, the capital intensive nature of HTS and difficulties in assay development for novel target classes are the factors that are curbing the growth of this market.
The HTS market is broadly classified into five segments, namely, technology, products, applications, end users, and geography. In the applications segment, the target identification market held the largest share of 45% in 2013. The availability of large compound libraries and well-equipped HTS laboratories, and technological advancements are the major factors driving the growth of this market. However, the primary screening market is poised to grow at the highest CAGR. The availability of a large number of potential lead compounds, emergence of several new detection technologies, and availability of novel primary and stem cell phenotypes are the factors that are responsible for the growth of this market segment. The growth in the outsourcing of drug services, especially in the Asian region, is a major reason for the high growth of the HTS market. In the end-users market, the pharmaceuticals segment dominated the market in 2013, with a market share of around 45%. In the technology market, the label-free technology segment is expected to register the highest growth in the forecast period. Label-free technology offers the direct detection ability, which was not possible with cell-based assays. Furthermore, it helps in reducing drug failure due to toxicity and can be applied to a majority of drug classes.
The global HTS market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The large market share of the North American region is attributed to the increased investments by drug discovery firms for the promotion and advancement of technologies and increasing number of collaborations among companies and academia to develop and distribute innovative HTS products.
The major players in the HTS market include Agilent Technologies (U.S.), PerkinElmer (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation) (U.S.), Sigma-Aldrich Corporation (U.S.), and Tecan group (Switzerland), among others.
Browse Related Reports:
Bioinformatics Market By Sector (Molecular Medicine, Agriculture, Research & Forensic), Segment (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & Application (Genomics, Proteomics & Drug Design) – Global Forecasts to 2017
Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012 – 2017) – (Neurodegenerative, Cardiovascular, Cancer & Autoimmune, Skin and Infectious Diseases)
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North – Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
For the original version on PRWeb visit: http://www.prweb.com/releases/high-throughput-screening/market/prweb11610006.htm